Patent intelligence · US
US 12150461
Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
Patent details — US 12150461
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 26, 2024
- Expiration
- Nov 21, 2044
- Applicant
- Sovida Solutions Ltd.
- Claims
- 5
- CPC classes
- A61K, A61K31/7084, A61K47/02, A61K47/10
Quick answer
US 12150461 (Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof) is held by Sovida Solutions Ltd.. Status: granted. Granted Nov 26, 2024. Expires Nov 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sovida Solutions Ltd.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/7084, A61K47/02, A61K47/10, A61K47/22, A61K47/24
More from Sovida Solutions Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12364708
Injectable scaffold for treatment of intracranial aneurysms and related technology
granted -
US 12358968
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
granted -
US 12336973
Cancer therapeutic compositions and methods targeting DNAse1L3
granted -
US 12329909
Airway management systems for pulmonary disorder treatment
granted -
US 12285397
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
granted -
US 12185909
System and method for cleansing segments of a luminal network
granted -
US 12144801
Methods and compositions for treatment of epileptic disorders
granted
Related coverage
Frequently asked questions
What is US patent 12150461?
US 12150461 (Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof) is held by Sovida Solutions Ltd.. Status: granted. Granted Nov 26, 2024. Expires Nov 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12150461?
Sovida Solutions Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 193 pharmaceutical patents for this assignee.
When does US 12150461 expire?
Our index shows an expiration date of Nov 21, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.